Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PLX
#3751
Protalix BioTherapeutics, Inc. Common Stock
2.125
0
USD
+0.24%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.24%
Monthly Change
+0.34%
6 month change
-27.23%
Year Change
-27.23%
Previous Close
2.120
0
Open
2.125
0
Low
2.115
0
High
2.140
0
Volume
264
Markets
US Stock Market
Healthcare
PLX
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Cash from operating activities
3.99 M
-5.06 M
-5.23 M
-3.73 M
2.03 M
-11.99 M
Cash from investing activities
-15.32 M
-312 K
-438 K
-504 K
-1.11 M
-2.37 M
Cash from financing activities
3.63 M
5.08 M
4.1 M
0
146 K
9.33 M
Free cash flow
3.57 M
-5.36 M
-5.66 M
-4.23 M
1.63 M
-13.63 M
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
News
Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX)
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX)
Brazil judge overrules decisions suspending changes to meal voucher system
A March Decision That Could Change Protalix’s Outlook (NYSE:PLX)
Pluxee, Edenred shares jump after upbeat results and outlook
Pluxee posts 9% growth in Q1; confirms 2026 outlook despite Brazil headwinds
Tuesday’s Insider Activity: Key Execs Make Notable Trades
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN)
Protalix and Secarna partner to develop rare kidney disease treatments
Pluxee revises fiscal 2026 outlook following Brazil regulatory changes
Deutsche Bank cuts Pluxee to “hold” after Brazil issues new voucher rules
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript